Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients ; volume:3 ; number:1 ; day:21 ; month:5 ; year:2024 ; pages:1-12 ; date:12.2024
Holistic integrative oncology ; 3, Heft 1 (21.5.2024), 1-12, 12.2024
- Urheber
-
Hao, Yiping
Ji, Min
Jin, Shumin
Li, Wei
Zhou, Ying
Jia, Ruinan
Li, Wěi
Jiang, Huihui
Wang, Jingtao
Lu, Fei
Zang, Shaolei
Zhang, Chunqing
Ye, Jingjing
Ji, Chunyan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s44178-024-00088-7
- URN
-
urn:nbn:de:101:1-2407292125292.286670234005
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hao, Yiping
- Ji, Min
- Jin, Shumin
- Li, Wei
- Zhou, Ying
- Jia, Ruinan
- Li, Wěi
- Jiang, Huihui
- Wang, Jingtao
- Lu, Fei
- Zang, Shaolei
- Zhang, Chunqing
- Ye, Jingjing
- Ji, Chunyan
- SpringerLink (Online service)
Ähnliche Objekte (12)
AML consolidation therapy: timing matters
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
Optimal Post-Remission Consolidation Therapy in Patients with AML
![Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].
Manipulation of SAMHD1 using lentiviral protein Vpx to increase sensitivity of AML cells to cytarabine
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
Disrupting the LC3 interaction region (LIR) binding of selective autophagy receptors sensitizes AML cell lines to cytarabine
Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
AML consolidation therapy: timing matters
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
Optimal Post-Remission Consolidation Therapy in Patients with AML
Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].
Manipulation of SAMHD1 using lentiviral protein Vpx to increase sensitivity of AML cells to cytarabine
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
Disrupting the LC3 interaction region (LIR) binding of selective autophagy receptors sensitizes AML cell lines to cytarabine
Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
AML consolidation therapy: timing matters
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
Optimal Post-Remission Consolidation Therapy in Patients with AML
Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].
Manipulation of SAMHD1 using lentiviral protein Vpx to increase sensitivity of AML cells to cytarabine
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
Disrupting the LC3 interaction region (LIR) binding of selective autophagy receptors sensitizes AML cell lines to cytarabine